查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786995

非何杰金氏淋巴瘤治疗药市场，规模，占有率，趋势，产业分析报告:细胞类别，治疗类别，各给药途径，各地区-2025年～2034年市场预测

Non-Hodgkin Lymphoma Therapeutics Market Size, Share, Trends, & Industry Analysis Report By Cell Type (B-cell lymphomas, T-cell lymphoma),By Therapy Type, By Route of Administration, and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，非何杰金氏淋巴瘤治疗市场预计到 2034 年将达到 189 亿美元。本研究报告深入分析了当前的市场动态，并分析了未来的市场成长。

非何杰金氏淋巴瘤治疗是指一系列针对各种淋巴瘤亚型的标靶疗法，着重疗效、安全性和延长患者存活期。这些疗法均遵循严格的临床标准研发，以确保精准性、一致性和良好的治疗效果。

市场成长的驱动力在于全球癌症发生率的上升以及对安全性更高的有效标靶疗法的迫切需求。癌症免疫疗法、单株抗体和 CAR-T 细胞疗法的进展正在改善復发和难治性非何杰金氏淋巴瘤的临床疗效。医疗保健投资和监管支持的增加，进一步加速了全球主要治疗中心对下一代淋巴瘤药物的开发和利用。

非何杰金氏淋巴瘤治疗市场报告重点

按细胞类型划分，B 细胞淋巴瘤预计在 2024 年占最大的市场占有率。这是由于 B 细胞淋巴瘤的高发病率以及标靶治疗方案的日益普及，这些方案可以提高缓解率和长期存活率。

按治疗类型划分，标靶治疗预计将快速成长，因为它们能够精准攻击癌细胞，同时最大限度地减少对健康组织的损害。

按给药途径划分，静脉给药，广泛应用于医院和肿瘤中心，用于控制剂量和疗效的生物製剂和化疗，预计将在 2024 年占主导地位。

预计北美将占全球非何杰金氏淋巴瘤市场的最大占有率。 2024 年淋巴瘤治疗市场将迎来强劲成长，这得益于强劲的医疗保健支出以及大型生物製药公司积极开发淋巴瘤治疗方案。

由于癌症负担的增加以及先进疗法的可及性提高，预计亚太地区的市场占有率在预测期内将以显着的复合年增长率增长。

全球主要市场参与者包括艾伯维公司 (AbbVie Inc.)、阿斯特捷利康公司 (AstraZeneca PLC)、百特国际公司 (Baxter International Inc.)、拜耳公司 (Bayer AG)、百时美施贵宝公司 (Bristol Myers Squibb Company)、礼来公司 (Eli Lilly and Company)、吉利罗氏製药公司 (Lader-fileb Company)、礼来公司 (Eli Lilly and Company)、吉利罗氏製药公司 (File Hile)、德来的公司 (Eli Lilly and Company)、File Cile 有限公司 (Eli Lilly K. Sciences, Inc.)、葛兰素史克公司 (GlaxoSmithKline PLC)、杨森生物技术公司 (Janssen Biotech, Inc.)、梯瓦製药工业有限公司 (Teva Pharmaceutical Industries Ltd.) 和 Verismo Therapeutics, Inc.。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球非何杰金氏淋巴瘤治疗药市场洞察

  • 市场概述
  • 非何杰金氏淋巴瘤治疗药市场动态
    • 促进因素和机会
      • 政府医疗支出不断增加
      • 全球非何杰金氏淋巴瘤 (NHL) 病例不断增加
    • 限制与挑战
      • 高昂的治疗费用
  • PESTEL分析
  • 非何杰金氏淋巴瘤治疗药市场趋势
  • 价值链分析

第5章 全球非何杰金氏淋巴瘤治疗药市场:细胞类别

  • 主要调查结果
  • 简介
  • B细胞淋巴瘤
  • T细胞淋巴瘤

第6章 全球非何杰金氏淋巴瘤治疗药市场:治疗类别

  • 主要调查结果
  • 简介
  • 化疗
  • 标靶治疗
  • 放射治疗
  • 其他的治疗方法

第7章 全球非何杰金氏淋巴瘤治疗药市场:各给药途径

  • 主要调查结果
  • 简介
  • 口服
  • 静脉内
  • 皮下

第8章 全球非何杰金氏淋巴瘤治疗药市场:各地区

  • 主要调查结果
  • 简介
    • 非何杰金氏淋巴瘤治疗药市场分析:地区，2020年～2034年
  • 北美
    • 北美:细胞类别，2020年～2034年
    • 北美:治疗类别，2020年～2034年
    • 北美:各给药途径，2020年～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:细胞类别，2020年～2034年
    • 欧洲:治疗类别，2020年～2034年
    • 欧洲:各给药途径，2020年～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:细胞类别，2020年～2034年
    • 亚太地区:治疗类别，2020年～2034年
    • 亚太地区:各给药途径，2020年～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:细胞类别，2020年～2034年
    • 中东·非洲:治疗类别，2020年～2034年
    • 中东·非洲:各给药途径，2020年～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东·非洲
  • 南美
    • 南美:细胞类别，2020年～2034年
    • 南美:治疗类别，2020-2034年
    • 南美:各给药途径，2020年～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • AbbVie Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann La-Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Janssen Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verismo Therapeutics, Inc.
Product Code: PM6004

The Non-Hodgkin lymphoma therapeutics market size is expected to reach USD 18.90 Billion by 2034, according to a new study by Polaris Market Research. The report "Non-Hodgkin Lymphoma Therapeutics Market Share, Size, Trends, Industry Analysis Report: By Cell Type (B-cell lymphomas, T-cell lymphoma), By Therapy Type, By Route of Administration, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-Hodgkin lymphoma therapeutics refer to a broad spectrum of targeted treatments designed to address diverse lymphatic cancer subtypes, focusing on efficacy, safety, and prolonged patient survival. These therapies are developed under stringent clinical standards to ensure precision, consistency, and favorable treatment response.

The market growth is fueled by increasing global cancer incidence and the urgent need for effective targeted therapies with improved safety profiles. Advancements in cancer immunotherapy, monoclonal antibodies, and CAR-T cell treatments are enhancing clinical outcomes for relapsed and refractory NHL cases. Rising healthcare investments and supportive regulatory pathways are further accelerating the development and accessibility of next-generation lymphoma therapeutics across major treatment centers worldwide.

Non-Hodgkin Lymphoma Therapeutics Market Report Highlights

Based on cell type, the B-cell lymphoma segment held largest share of the market in 2024, due to its high prevalence and growing availability of targeted treatment options that improve remission rates and long-term survival outcomes.

Based on therapy type, the targeted therapy segment is expected to witness the fastest growth, due to its precision in attacking cancerous cells while minimizing damage to healthy tissue

Based on route of administration, the intravenous segment held the dominant market share in 2024, driven by the widespread use in hospitals and oncology centers for delivering biologics and chemotherapy with controlled dosage and efficacy.

North America accounted for largest share of the global non-hodgkin lymphoma therapeutics market in 2024, fueled by strong healthcare spending and the presence of leading biopharmaceutical companies engaged in lymphoma drug development.

Asia Pacific is expected to grow with a significant CAGR during the forecast period market share, due to the growing cancer burden and increased access to advanced therapies.

A few global key market players include AbbVie Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Janssen Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Verismo Therapeutics, Inc.

Polaris Market Research has segmented the market report on the basis of cell type, therapy type, route of administration, and region:

By Cell Type Outlook (Revenue, USD Billion, 2020-2034)

B-cell lymphomas

T-cell lymphoma

By Therapy Type Outlook (Revenue, USD Billion, 2020-2034)

Chemotherapy

Targeted therapy

Radiation therapy

Other therapy types

By Route of Administration (Revenue, USD Billion, 2020-2034)

Oral

Intravenous

Subcutaneous

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-Hodgkin Lymphoma Therapeutics Market Insights

  • 4.1. Non-Hodgkin Lymphoma Therapeutics Market - Market Snapshot
  • 4.2. Non-Hodgkin Lymphoma Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Government Healthcare Spending
      • 4.2.1.2. Rising Cases of NHL Worldwide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-Hodgkin Lymphoma Therapeutics Market Trends
  • 4.6. Value Chain Analysis

5. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • 5.3. B-cell lymphomas
    • 5.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell lymphomas, by Region, 2020-2034 (USD Billion)
  • 5.4. T-cell lymphomas
    • 5.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell lymphomas, by Region, 2020-2034 (USD Billion)

6. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Targeted Therapy
    • 6.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 6.5. Radiation Therapy
    • 6.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 6.6. Other Therapy Types
    • 6.6.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Therapy Types, by Region, 2020-2034 (USD Billion)

7. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 7.4. Intravenous
    • 7.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Intravenous, by Region, 2020-2034 (USD Billion)
  • 7.5. Subcutaneous
    • 7.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Subcutaneous, by Region, 2020-2034 (USD Billion)

8. Global Non-Hodgkin Lymphoma Therapeutics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-Hodgkin Lymphoma Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-Hodgkin Lymphoma Therapeutics Market - North America
    • 8.3.1. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.4. Non-Hodgkin Lymphoma Therapeutics Market - US
      • 8.3.4.1. US: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.5. Non-Hodgkin Lymphoma Therapeutics Market - Canada
      • 8.3.5.1. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.4. Non-Hodgkin Lymphoma Therapeutics Market - Europe
    • 8.4.1. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.4. Non-Hodgkin Lymphoma Therapeutics Market - UK
      • 8.4.4.1. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.5. Non-Hodgkin Lymphoma Therapeutics Market - France
      • 8.4.5.1. France: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.6. Non-Hodgkin Lymphoma Therapeutics Market - Germany
      • 8.4.6.1. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.7. Non-Hodgkin Lymphoma Therapeutics Market - Italy
      • 8.4.7.1. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.8. Non-Hodgkin Lymphoma Therapeutics Market - Spain
      • 8.4.8.1. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.9. Non-Hodgkin Lymphoma Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.10. Non-Hodgkin Lymphoma Therapeutics Market - Russia
      • 8.4.10.1. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.5. Non-Hodgkin Lymphoma Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.4. Non-Hodgkin Lymphoma Therapeutics Market - China
      • 8.5.4.1. China: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.5. Non-Hodgkin Lymphoma Therapeutics Market - India
      • 8.5.5.1. India: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.6. Non-Hodgkin Lymphoma Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.7. Non-Hodgkin Lymphoma Therapeutics Market - Japan
      • 8.5.7.1. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.8. Non-Hodgkin Lymphoma Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.9. Non-Hodgkin Lymphoma Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.10. Non-Hodgkin Lymphoma Therapeutics Market - Australia
      • 8.5.10.1. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.6. Non-Hodgkin Lymphoma Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.4. Non-Hodgkin Lymphoma Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.5. Non-Hodgkin Lymphoma Therapeutics Market - UAE
      • 8.6.5.1. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.6. Non-Hodgkin Lymphoma Therapeutics Market - Israel
      • 8.6.6.1. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.7. Non-Hodgkin Lymphoma Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.8. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.7. Non-Hodgkin Lymphoma Therapeutics Market - Latin America
    • 8.7.1. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.4. Non-Hodgkin Lymphoma Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.5. Non-Hodgkin Lymphoma Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.6. Non-Hodgkin Lymphoma Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.7. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Cell Type Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca PLC
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Cell Type Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Baxter International Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Cell Type Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bayer AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Cell Type Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol Myers Squibb Company
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Cell Type Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Eli Lilly and Company
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Cell Type Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann La-Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Cell Type Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Gilead Sciences, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Cell Type Benchmarking
    • 10.8.4. Recent Development
  • 10.9. GlaxoSmithKline PLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Cell Type Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Janssen Biotech, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Cell Type Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Teva Pharmaceutical Industries Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Cell Type Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Verismo Therapeutics, Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Cell Type Benchmarking
    • 10.12.4. Recent Development

List of Tables:

  • Table 1 Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 2 Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 3 Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 4 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 5 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 6 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 7 US: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 8 US: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 9 US: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 10 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 12 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 13 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 15 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 16 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 17 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 18 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 19 France: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 20 France: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 21 France: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 22 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 24 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 25 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 27 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 28 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 30 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 34 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 36 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 43 China: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 44 China: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 45 China: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 46 India: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 47 India: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 48 India: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 52 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 54 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 58 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 60 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 61 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 63 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 73 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 75 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 76 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 78 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 79 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 81 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 85 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 87 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 88 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 90 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 91 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 93 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 94 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 96 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Non-Hodgkin Lymphoma Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Cell Type
  • Figure 7. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy Type
  • Figure 9. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2024 & 2034 (USD Billion)